Acumen Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the symbol ABOS, based in Newton, Massachusetts, shared on September 2, 2026, that they will be involved in some investor conferences. The company focuses on creating new treatments to combat Alzheimer’s disease by targeting toxic soluble amyloid beta oligomers.